Paramagnetic liposomes for molecular MRI and MRI-guided drug delivery

NMR in Biomedicine

Volumn 26, Issue 7, 2013, Pages 728-744

  Langereis, Sander ^a   Geelen, Tessa ^b   Grüll, Holger ^a,b   Strijkers, Gustav J ^b   Nicolay, Klaas ^b  

^a PHILIPS RESEARCH LABORATORIES   (Netherlands)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

Image guided drug delivery; Liposomes; Molecular MRI; Target specific contrast agents

Indexed keywords

COMPARTMENTALIZATION EFFECTS; CONTRAST AGENT; ENDOTHELIAL DYSFUNCTION; IMAGE-GUIDED; MOLECULAR MRIS; MRI CONTRAST AGENTS; MYOCARDIAL INFARCTION; THERAPEUTIC INTERVENTION;

CELL MEMBRANES; DRUG DELIVERY; LIPOSOMES; MAGNETIC RESONANCE IMAGING; PARAMAGNETISM;

MOLECULAR IMAGING;

CELL RECEPTOR; INTERNALIZING CELL RECEPTOR; LIGAND; LIPOSOME; PARAMAGNETIC LIPOSOMES; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COMPARTMENTALIZATION; CELL VIABILITY; CELLULAR IMAGING; CONTRAST ENHANCEMENT; CONTRAST MEDIUM EXTRAVASATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DELIVERY SYSTEM; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; IMAGE ANALYSIS; IMAGING AND DISPLAY; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MODULATION; MOLECULAR IMAGING; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANIMALS; CONTRAST MEDIA; DRUG DELIVERY SYSTEMS; HUMANS; LIPOSOMES; MAGNETIC PHENOMENA; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING;

EID: 84879551255     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.2971     Document Type: Article

References (201)

1. Jaffer FA, Libby P, Weissleder R. Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2009; 29: 1017-1024.
2. Badr CE, Tannous BA. Bioluminescence imaging: progress and applications. Trends Biotechnol. 2011; 29: 624-633.
3. Louie A. Multimodality imaging probes: design and challenges. Chem. Rev. 2010; 110: 3146-3195.
4. Cherry SR. Multimodality imaging: beyond PET/CT and SPECT/CT. Semin. Nucl. Med. 2009; 39: 348-353.
5. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem. Rev. 1999; 99: 2293-2352.
6. Strijkers GJ, Nicolay K. Relaxivity of nanoparticles for magnetic resonance imaging. In: Sattler KD (ed.). Handbook of Nanophysics: Nanomedicine and Nanorobotics. CRC Press: Boca Raton; 2011, Chapter 23, pp. 1-23.
7. de Lussanet QG, Langereis S, Beets-Tan RG, van Genderen MH, Griffioen AW, van Engelshoven JM, Backes WH. Dynamic contrast-enhanced MR imaging kinetic parameters and molecular weight of dendritic contrast agents in tumor angiogenesis in mice. Radiology, 2005; 235: 65-72.
8. Choyke PL. Contrast agents for imaging tumor angiogenesis: is bigger better? Radiology, 2005; 235: 1-2.
9. Mikulis DJ, Roberts TP. Neuro MR: protocols. J. Magn. Reson. Imaging, 2007; 26: 838-847.
10. Schnall MD. Breast MR imaging. Radiol. Clin. North Am. 2003; 41: 43-50.
11. Weissleder R, Mahmood U. Molecular imaging. Radiology, 2001; 219: 316-333.
12. Pysz MA, Gambhir SS, Willmann JK. Molecular imaging: current status and emerging strategies. Clin. Radiol. 2010; 65: 500-516.
13. James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol. Rev. 2012; 92: 897-965.
14. Nunn AD, Linder KE, Tweedle MF. Can receptors be imaged with MRI agents? Q. J. Nucl. Med. 1997; 41: 155-162.
15. Frangioni JV. New technologies for human cancer imaging. J. Clin. Oncol. 2008; 26: 4012-4021.
16. Kuhl TL, Leckband DD, Lasic DD, Israelachvili JN. Modulation of interaction forces between bilayers exposing short-chained ethylene oxide headgroups. Biophys. J. 1994; 66: 1479-1488.
17. Allen C, Dos Santos N, Gallagher R, Chiu GNC, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD, Webb MS, Bally MB. Controlling the physical behavior and biological performace of liposome formulations through use of surface grafted poly(ethylene glycol). Biosci. Rep. 2002; 22: 223-250.
18. Kobayashi H, Kawamoto S, Jo S-K, Bryant HL Jr, Brechbiel MW, Star RA. Macromolecular MRI contrast agents with small dendrimers: pharmacokinetic differences between sizes and cores. Bioconjug. Chem. 2003; 14: 388-394.
19. Langereis S, de Lussanet QG, van Genderen MHP, Meijer EW, Beets-Tan RGH, Griffioen AW, van Engelshoven JMA, Backes WH. Evaluation of Gd(III)DTPA-terminated poly(propylene imine) dendrimers as contrast agents for MR imaging. NMR Biomed. 2006; 19: 133-141.
20. Dong Q, Hurst DR, Weinmann HJ, Chenevert TL, Londy FJ, Prince MR. Magnetic resonance angiography with gadomer-17. An animal study original investigation. Invest. Radiol. 1998; 33: 699-708.
21. Langereis S, Dirksen A, Hackeng TM, van Genderen MHP, Meijer EW. Dendrimers and magnetic resonance imaging. New J. Chem. 2007; 31: 1152-1160.
22. Pikkemaat JA, Wegh RT, Lamerichs R, van de Molengraaf RA, Langereis S, Burdinski D, Raymond AYF, Janssen HM, de Waal BFM, Willard NP, Meijer EW, Grüll H. Dendritic PARACEST contrast agents for magnetic resonance imaging. Contrast Media Mol. Imaging, 2007; 2: 229-239.
23. Kobayashi H, Brechbiel MW. Nano-sized MRI contrast agents with dendrimer cores. Adv. Drug Deliv. Rev. 2005; 57: 2271-2286.
24. Kobayashi H, Sato N, Hiraga A, Saga T, Nakamoto Y, Ueda H, Konishi J, Togashi K, Brechbiel MW. 3D-micro-MR angiography of mice using macromolecular MR contrast agents with polyamidoamine dendrimer core with reference to their pharmacokinetic properties. Magn. Reson. Med. 2001; 45: 454-460.
25. Sato N, Kobayashi H, Hiraga A, Saga T, Togashi K, Konishi J, Brechbiel MW. Pharmacokinetics and enhancement patterns of macromolecular MR contrast agents with various sizes of polyamidoamine dendrimer cores. Magn. Reson. Med. 2001; 46: 1169-1173.
26. Hovland R, Glogard C, Aasen AJ, Klaveness J. Preparation and in vitro evaluation of a novel amphiphilic GdPCTA-[12] derivative; a micellar MRI contrast agent. Org. Biomol. Chem. 2003; 1: 644-647.
27. Accardo A, Tesauro D, Roscigno P, Gianolio E, Paduano L, D'Errico G, Pedone C, Morelli G. Physicochemical properties of mixed micellar aggregates containing CCK peptides and Gd complexes designed as tumor specific contrast agents in MRI. J. Am. Chem. Soc. 2004; 126: 3097-3107.
28. Torchilin VP. PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv. Drug Deliv. Rev. 2002; 54: 235-252.
29. van Tilborg GA, Mulder WJ, Chin PT, Storm G, Reutelingsperger CP, Nicolay K, Strijkers GJ. Annexin A5-conjugated quantum dots with a paramagnetic lipidic coating for the multimodal detection of apoptotic cells. Bioconjug. Chem. 2006; 17: 865-868.
30. Koole R, van Schooneveld MM, Hilhorst J, Castermans K, Cormode DP, Strijkers GJ, de Mello Donega C, Vanmaekelbergh D, Griffioen AW, Nicolay K, Fayad ZA, Meijerink A, Mulder WJ. Paramagnetic lipid-coated silica nanoparticles with a fluorescent quantum dot core: a new contrast agent platform for multimodality imaging. Bioconjug. Chem. 2008; 19: 2471-2479.
31. Cormode DP, Skajaa T, Fayad ZA, Mulder WJ. Nanotechnology in medical imaging: probe design and applications. Arterioscler. Thromb. Vasc. Biol. 2009; 29: 992-1000.
32. Koole R, Mulder WJ, van Schooneveld MM, Strijkers GJ, Meijerink A, Nicolay K. Magnetic quantum dots for multimodal imaging. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009; 1: 475-491.
33. van Schooneveld MM, Vucic E, Koole R, Zhou Y, Stocks J, Cormode DP, Tang CY, Gordon RE, Nicolay K, Meijerink A, Fayad ZA, Mulder WJ. Improved biocompatibility and pharmacokinetics of silica nanoparticles by means of a lipid coating: a multimodality investigation. Nano Lett. 2008; 8: 2517-2525.
34. Mulder WJ, Strijkers GJ, Nicolay K, Griffioen AW. Quantum dots for multimodal molecular imaging of angiogenesis. Angiogenesis, 2010; 13: 131-134.
35. Starmans LW, Kok MB, Sanders HM, Zhao Y, Donega Cde M, Meijerink A, Mulder WJ, Grüll H, Strijkers GJ, Nicolay K. Influence of cell-internalization on relaxometric, optical and compositional properties of targeted paramagnetic quantum dot micelles. Contrast Media Mol. Imaging, 2011; 6: 100-109.
36. Mulder WJ, Koole R, Brandwijk RJ, Storm G, Chin PT, Strijkers GJ, de Mello Donega C, Nicolay K, Griffioen AW. Quantum dots with a paramagnetic coating as a bimodal molecular imaging probe. Nano Lett. 2006; 6: 1-6.
37. Kaneda MM, Caruthers S, Lanza GM, Wickline SA. Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann. Biomed. Eng. 2009; 37: 1922-1933.
38. 19F MRS of cell-internalized perfluorocarbon paramagnetic nanoparticles. Contrast Media Mol. Imaging, 2011; 6: 19-27.
39. Bulte JW. Hot spot MRI emerges from the background. Nat. Biotechnol. 2005; 23: 945-946.
40. Chen J, Lanza GM, Wickline SA. Quantitative magnetic resonance fluorine imaging: today and tomorrow. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2010; 2: 431-440.
41. Caruthers SD, Winter PM, Wickline SA, Lanza GM. Targeted magnetic resonance imaging contrast agents. Methods Mol. Med. 2006; 124: 387-400.
42. Mulder WJ, Strijkers GJ, van Tilborg GA, Griffioen AW, Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed. 2006; 19: 142-164.
43. Devoisselle JM, Vion-Dury J, Galons JP, Confort-Gouny S, Coustaut D, Canioni P, Cozzone PJ. Entrapment of gadolinium-DTPA in liposomes. Characterization of vesicles by P-31 NMR spectroscopy. Invest. Radiol. 1988; 23: 719-724.
44. Kabalka GW, Buonocore E, Hubner K, Davis M, Huang L. Gadolinium-labeled liposomes containing paramagnetic amphipathic agents: targeted MRI contrast agents for the liver. Magn. Reson. Med. 1988; 8: 89-95.
45. Mulder WJ, Strijkers GJ, van Tilborg GA, Cormode DP, Fayad ZA, Nicolay K. Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. Acc. Chem. Res. 2009; 42: 904-914.
46. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol. Pharm. 2008; 5: 496-504.
47. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discov. 2005; 4: 145-160.
48. Maeda H. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 2010; 21: 797-802.
49. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature, 2000; 407: 249-257.
50. Cheng Z, Al Zaki A, Hui JZ, Muzykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science, 2012; 338: 903-910.
51. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46: 6387-6392.
52. Danhier F, Feron O, Preat V. To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J. Control. Release, 2010; 148: 135-146.
53. Gabizon A. Pharmacokinetics of PEGylated liposomal doxorubicin. Clin. Pharmacokinet. 2003; 42: 419-436.
54. Drummond DC, Noble CO, Hayes ME, Park JW, Kirpotin DB. Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development. J. Pharm. Sci. 2008; 97: 4696-4740.
55. Abraham SA, Waterhouse DN, Lawrence D, Mayer D, Cullis PR, Madden TD, Bally MB. The liposomal formulation of doxorubicin. Methods Enzymol. 2005; 391: 71-97.
56. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano 2009; 3: 16-20.
57. Hak S, Sanders HM, Agrawal P, Langereis S, Grüll H, Keizer HM, Arena F, Terreno E, Strijkers GJ, Nicolay K. A high relaxivity Gd(III)DOTA-DSPE-based liposomal contrast agent for magnetic resonance imaging. Eur. J. Pharm. Biopharm. 2009; 72: 397-404.
58. Bangham AD. Surrogate cells or Trojan horses. The discovery of liposomes. Bioessays, 1995; 17: 1081-1088.
59. Strijkers GJ, Kluza E, Van Tilborg GA, van der Schaft DW, Griffioen AW, Mulder WJ, Nicolay K. Paramagnetic and fluorescent liposomes for target-specific imaging and therapy of tumor angiogenesis. Angiogenesis, 2010; 13: 161-173.
60. Caride VJ, Sostman HD, Winchell RJ, Gore JC. Relaxation enhancement using liposomes carrying paramagnetic species. Magn. Reson. Imaging, 1984; 2: 107-112.
61. Magin RL, Wright SM, Niesman MR, Chan HC, Swartz HM. Liposome delivery of NMR contrast agents for improved tissue imaging. Magn. Reson. Med. 1986; 3: 440-447.
62. Caride VJ. Liposomes as carriers of imaging agents. Crit. Rev. Ther. Drug Carrier Syst. 1985; 1: 121-153.
63. Fossheim SL, Fahlvik AK, Klaveness J, Muller RN. Paramagnetic liposomes as MRI contrast agents: influence of liposomal physicochemical properties on the in vitro relaxivity. Magn. Reson. Imaging, 1999; 17: 83-89.
64. Terreno E, Cabella C, Carrera C, Delli Castelli D, Mazzon R, Rollet S, Stancanello J, Visigalli M, Aime S. From spherical to osmotically shrunken paramagnetic liposomes: an improved generation of LIPOCEST MRI agents with highly shifted water protons. Angew. Chem. Int. Ed Engl. 2007; 46: 966-968.
65. Kabalka G, Buonocore E, Hubner K, Moss T, Norley N, Huang L. Gadolinium-labeled liposomes: targeted MR contrast agents for the liver and spleen. Radiology, 1987; 163: 255-258.
66. Schwendener RA, Wuthrich R, Duewell S, Wehrli E, von Schulthess GK. A pharmacokinetic and MRI study of unilamellar gadolinium-, manganese-, and iron-DTPA-stearate liposomes as organ-specific contrast agents. Invest. Radiol. 1990; 25: 922-932.
67. Tilcock C, Ahkong QF, Koenig SH, Brown RD, Davis M, Kabalka G. The design of liposomal paramagnetic MR agents: effect of vesicle size upon the relaxivity of surface-incorporated lipophilic chelates. Magn. Reson. Med. 1992; 27: 44-51.
68. Glogard C, Stensrud G, Hovland R, Fossheim SL, Klaveness J. Liposomes as carriers of amphiphilic gadolinium chelates: the effect of membrane composition on incorporation efficacy and in vitro relaxivity. Int. J. Pharm. 2002; 233: 131-140.
69. Laurent S, Vander Elst L, Thirifays C, Muller RN. Relaxivities of paramagnetic liposomes: on the importance of the chain type and the length of the amphiphilic complex. Eur. Biophys. J. 2008; 37: 1007-1014.
70. Strijkers GJ, Mulder WJ, van Heeswijk RB, Frederik PM, Bomans P, Magusin PC, Nicolay K. Relaxivity of liposomal paramagnetic MRI contrast agents. Magn. Reson. Mater. Phys. 2005; 18: 186-192.
71. Kamaly N, Kalber T, Ahmad A, Oliver MH, So PW, Herlihy AH, Bell JD, Jorgensen MR, Miller AD. Bimodal paramagnetic and fluorescent liposomes for cellular and tumor magnetic resonance imaging. Bioconjug. Chem. 2008; 19: 118-129.
72. Kim SK, Pohost GM, Elgavish GA. Fatty-acyl iminopolycarboxylates: lipophilic bifunctional contrast agents for NMR imaging. Magn. Reson. Med. 1991; 22: 57-67.
73. Hak S, Sanders HMHF, Strijkers GJ, Nicolay K. Lipid-based nanoparticles as MRI contrast agents: characterization and application. In: Nalwa HS (ed.). Encyclopedia of Nanoscience and Nanotechnology, Vol. 15. American Scientific Publishers: Stevenson Ranch, CA; 2011; 493-519.
74. Storrs RW, Tropper FD, Li HY, Song CK, Kuniyoshi JK, Sipkins DA, Li KCP, Bednarski MD. Paramagnetic polymerized liposomes: synthesis, characterization, and applications for magnetic resonance imaging. J. Am. Chem. Soc. 1995; 117: 7301-7306.
75. Bacic G, Niesman MR, Bennett HF, Magin RL, Swartz HM. Modulation of water proton relaxation rates by liposomes containing paramagnetic materials. Magn. Reson. Med. 1988; 6: 445-458.
76. Laurent S, Elst LV, Thirifays C, Muller RN. Paramagnetic liposomes: inner versus outer membrane relaxivity of DPPC liposomes incorporating lipophilic gadolinium complexes. Langmuir, 2008; 24: 4347-4351.
77. Geelen T, Paulis LE, Coolen BF, Nicolay K, Strijkers GJ. Passive targeting of lipid-based nanoparticles to mouse cardiac ischemia-reperfusion injury. Contrast Media Mol. Imaging, 2013; 8: 117-126.
78. Paulis LE, Geelen T, Kuhlmann MT, Coolen BF, Schäfers M, Nicolay K, Strijkers GJ. Distribution of lipid-based nanoparticles to infarcted myocardium with potential application for MRI-monitored drug delivery. J. Control. Release, 2012; 162: 276-285.
79. Morawski AM, Winter PM, Crowder KC, Caruthers SD, Fuhrhop RW, Scott MJ, Robertson JD, Abendschein DR, Lanza GM, Wickline SA. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn. Reson. Med. 2004; 51: 480-486.
80. van Bochove GS, Paulis LE, Segers D, Mulder WJ, Krams R, Nicolay K, Strijkers GJ. Contrast enhancement by differently sized paramagnetic MRI contrast agents in mice with two phenotypes of atherosclerotic plaque. Contrast Media Mol. Imaging, 2011; 6: 35-45.
81. Maiseyeu A, Mihai G, Kampfrath T, Simonetti OP, Sen CK, Roy S, Rajagopalan S, Parthasarathy S. Gadolinium-containing phosphatidylserine liposomes for molecular imaging of atherosclerosis. J. Lipid Res. 2009; 50: 2157-2163.
82. Geelen T, Yeo SY, Paulis LE, Starmans LW, Nicolay K, Strijkers GJ. Internalization of paramagnetic phosphatidylserine-containing liposomes by macrophages. J. Nanobiotechnol. 2012; 10: 37.
83. Reulen SW, Brusselaars WW, Langereis S, Mulder WJ, Breurken M, Merkx M. Protein-liposome conjugates using cysteine-lipids and native chemical ligation. Bioconjug. Chem. 2007; 18: 590-596.
84. Sanders HM, Strijkers GJ, Mulder WJ, Huinink HP, Erich SJ, Adan OC, Sommerdijk NA, Merkx M, Nicolay K. Morphology, binding behavior and MR-properties of paramagnetic collagen-binding liposomes. Contrast Media Mol. Imaging, 2009; 4: 81-88.
85. Huinink HP, Sanders HM, Erich SJ, Nicolay K, Strijkers GJ, Merkx M, Adan OC. High-resolution NMR imaging of paramagnetic liposomes targeted to a functionalized surface. Magn. Reson. Med. 2008; 59: 1282-1286.
86. Sanders HM, Iafisco M, Pouget EM, Bomans PH, Nudelman F, Falini G, de With G, Merkx M, Strijkers GJ, Nicolay K, Sommerdijk NA. The binding of CNA35 contrast agents to collagen fibrils. Chem. Commun. 2011; 47: 1503-1505.
87. Zong YN, Xu Y, Liang XW, Keene DR, Hook A, Gurusiddappa S, Hook M, Narayana SVL. A 'collagen hug' model for Staphylococcus aureus CNA binding to collagen. EMBO J. 2005; 24: 4224-4236.
88. van Tilborg GA, Mulder WJ, Deckers N, Storm G, Reutelingsperger CP, Strijkers GJ, Nicolay K. Annexin A5-functionalized bimodal lipid-based contrast agents for the detection of apoptosis. Bioconjug. Chem. 2006; 17: 741-749.
89. Hengartner MO. The biochemistry of apoptosis. Nature, 2000; 407: 770-776.
90. Gerke V, Moss SE. Annexins: from structure to function. Physiol. Rev. 2002; 82: 331-371.
91. Paulis LE, Jacobs I, van de Akker NM, Geelen T, Molin DG, Starmans LW, Nicolay K, Strijkers GJ. Targeting of ICAM-1 on vascular endothelium under static and shear stress conditions using a liposomal Gd-based MRI contrast agent. J. Nanobiotechnol. 2012; 10: 25.
92. Auerbach SD, Yang L, Luscinskas FW. Endothelial ICAM-1 functions in adhesion and signaling during leukocyte recruitment. In: Ley K (ed.). Adhesion Molecules: Function and Inhibition. Birkhauser: Basel; 2007, pp. 99-116.
93. Brandwijk RJ, Mulder WJM, Nicolay K, Mayo KH, Thijssen VLJL, Griffioen AW. Anginex-conjugated liposomes for targeting of angiogenic endothelial cells. Bioconjug. Chem. 2007; 18: 785-790.
94. Mulder WJ, Strijkers GJ, Griffioen AW, van Bloois L, Molema G, Storm G, Koning GA, Nicolay K. A liposomal system for contrast-enhanced magnetic resonance imaging of molecular targets. Bioconjug. Chem. 2004; 15: 799-806.
95. Erdogan S, Roby A, Sawant R, Hurley J, Torchilin VP. Gadolinium-loaded polychelating polymer-containing cancer cell-specific immunoliposomes. J. Liposome Res. 2006; 16: 45-55.
96. Esposito G, Crich SG, Aime S. Efficient cellular labeling by CD44 receptor-mediated uptake of cationic liposomes functionalized with hyaluronic acid and loaded with MRI contrast agents. ChemMedChem 2008; 3: 1858-1862.
97. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM. Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J. Immunol. 1992; 148: 2207-2216.
98. Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol. Rev. 2000; 52: 237-268.
99. 2 relaxivity. Magn. Reson. Med. 2009; 61: 1022-1032.
100. 1 relaxation model for intracellular paramagnetic contrast agents. Magn. Reson. Med. 2009; 61: 1049-1058.
101. Gianolio E, Arena F, Strijkers GJ, Nicolay K, Hogset A, Aime S. Photochemical activation of endosomal escape of MRI-Gd-agents in tumor cells. Magn. Reson. Med. 2011; 65: 212-219.
102. 19F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla. Invest. Radiol. 2006; 41: 305-312.
103. Morawski AM, Winter PM, Yu X, Fuhrhop RW, Scott MJ, Hockett F, Robertson JD, Gaffney PJ, Lanza GM, Wickline SA. Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. Magn. Reson. Med. 2004; 52: 1255-1262.
104. Flögel U, Ding Z, Hardung H, Jander S, Reichmann G, Jacoby C, Schubert R, Schrader J. In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation, 2008; 118: 140-148.
105. de Vries A, Kok MB, Sanders HMHF, Nicolay K, Strijkers GJ, Grüll H. Multimodal liposomes for SPECT/MR imaging as a tool for in situ relaxivity measurements. Contrast Media Mol. Imaging, 2012; 7: 68-75.
106. Reulen SW, Merkx M. Exchange kinetics of protein-functionalized micelles and liposomes studied by Förster resonance energy transfer. Bioconjug. Chem. 2010; 21: 860-866.
107. Skajaa T, Zhao Y, Van Den Heuvel DJ, Gerritsen HC, Cormode DP, Koole R, Van Schooneveld MM, Post JA, Fisher EA, Fayad ZA, De Mello Donega C, Meijerink A, Mulder WJM. Quantum dot and Cy5.5 labeled nanoparticles to investigate lipoprotein biointeractions via Förster resonance energy transfer. Nano Lett. 2010; 10: 5131-5138.
108. 1H-MR relaxometric properties of cell-internalized paramagnetic liposomes, as studied over a five-day period. Contrast Media Mol. Imaging, 2011; 6: 69-76.
109. 3-integrin-expressing glioma cells and only accumulates in the vascular tumor compartment. Radiology, 2009; 253: 462-469.
110. Unger E, Needleman P, Cullis P, Tilcock C. Gadolinium-DTPA liposomes as a potential. Work in progress. Invest. Radiol. 1988; 23: 928-932.
111. Unger E, Cardenas D, Zerella A, Fajardo LL, Tilcock C. Biodistribution and clearance of liposomal gadolinium-DTPA. Invest. Radiol. 1990; 25: 638-644.
112. Kabalka GW, Davis MA, Moss TH, Buonocore E, Hubner K, Holmberg E, Maruyama K, Huang L. Gadolinium-labeled liposomes containing various amphiphilic Gd-DTPA derivatives: targeted MRI contrast enhancement agents for the liver. Magn. Reson. Med. 1991; 19: 406-415.
113. Karlik S, Florio E, Grant CW. Comparative evaluation of two membrane-based liposomal MRI contrast agents. Magn. Reson. Med. 1991; 19: 56-66.
114. Howles GP, Ghaghada KB, Qi Y, Mukundan S, Johnson GA. High-resolution magnetic resonance angiography in the mouse using a nanoparticle blood-pool contrast agent. Magn. Reson. Med. 2009; 62: 1447-1456.
115. Bucholz E, Ghaghada K, Qi Y, Mukundan S, Johnson GA. Four-dimensional MR microscopy of the mouse heart using radial acquisition and lipopsomal gadolinium contrast agent. Magn. Reson. Med. 2008; 60: 111-118.
116. Weissig V, Babich J, Torchilin V. Long-circulating gadolinium-loaded liposomes: potential use for magnetic resonance imaging of the blood pool. Colloids Surf. B Biointerfaces, 2000; 18: 293-299.
117. Storrs RW, Tropper FD, Li HY, Song CK, Sipkins DA, Kuniyoshi JK, Bednarski MD, Strauss HW, Li KCP. Paramagnetic polymerized liposomes as new recirculating MR contrast agents. J. Magn. Reson. Imaging, 1995; 5: 719-724.
118. Unger EC, Winokur T, MacDougall P, Rosenblum J, Clair M, Gatenby R, Tilcock C. Hepatic metastases: liposomal Gd-DTPA-enhanced MR imaging. Radiology, 1989; 171: 81-85.
119. Unger EC, MacDougall P, Cullis P, Tilcock C. Liposomal gadolinium-DTPA: effect of encapsulation on enhancement of hepatoma model by MRI. Magn. Reson. Imaging, 1989; 7: 417-423.
120. Bertini I, Bianchini F, Calorini L, Colagrande S, Fragai M, Franchi A, Gallo O, Gavazzi C, Luchinat C. Persistent contrast enhancement by sterically stabilized paramagnetic liposomes in murine melanoma. Magn. Reson. Med. 2004; 52: 669-672.
121. Kamaly N, Kalber T, Kenny G, Bell J, Jorgensen M, Miller A. A novel bimodal lipidic contrast agent for cellular labelling and tumour MRI. Org. Biomol. Chem. 2010; 8: 201-211.
122. 1 mapping. J. Cardiovasc. Magn. Reson. 2011; 13: 56.
123. Mulder WJ, Douma K, Koning GA, van Zandvoort MA, Lutgens E, Daemen MJ, Nicolay K, Strijkers GJ. Liposome-enhanced MRI of neointimal lesions in the ApoE-KO mouse. Magn. Reson. Med. 2006; 55: 1170-1174.
124. den Adel B, van der Graaf LM, Que I, Strijkers GJ, Löwik CW, Poelmann RE, van der Weerd L. Contrast enhancement by lipid-based MRI contrast agents in mouse atherosclerotic plaques; a longitudinal study. Contrast Media Mol. Imaging, 2013; 8: 63-71.
125. Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC. Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat. Med. 1998; 4: 623-626.
126. Mulder WJ, Strijkers GJ, Habets JW, Bleeker EJ, van der Schaft DW, Storm G, Koning GA, Griffioen AW, Nicolay K. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidic nanoparticle. FASEB J. 2005; 19: 2008-2010.
127. Dong Z, Xiao-Yuan F, Henning TD, Li W, Wei-Yue L, Hong P, Xing W, Li-Gang Z. MR imaging of tumor angiogenesis using sterically stabilized Gd-DTPA liposomes targeted to CD105. Eur. J. Radiol. 2009; 70: 180-189.
128. Mulder WJ, van der Schaft DW, Hautvast PA, Strijkers GJ, Koning GA, Storm G, Mayo KH, Griffioen AW, Nicolay K. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEB J. 2007; 21: 378-383.
129. Sipkins DA, Gijbels MJ, Tropper FD, Bednarski M, Li KCP, Steinman L. ICAM-1 expression in autoimmune encephalitis visualized using magnetic resonance imaging. J. Neuroimmunol. 2000; 104: 1-9.
130. Deddens LH, Van Tilborg GAF, van der Toorn A, van der Marel K, Paulis LEM, Van Bloois L, Storm G, Strijkers GJ, Mulder WJM, de Vries HE, Dijkhuizen RM. MRI of ICAM-1 upregulation after stroke: the importance of choosing the appropriate target-specific particulate contrast agent. Mol. Imaging Biol. 2013. doi: 10.1007/s11307-11013-10617-z.
131. 1-shortening liposomes. Radiology, 2012; 264: 428-435.
132. Kamaly N, Kalber T, Thanou M, Bell JD, Miller AD. Folate receptor targeted bimodal liposomes for tumor magnetic resonance imaging. Bioconjug. Chem. 2009; 20: 648-655.
133. Chekhonin VP, Bakklaushev VP, Yusubalieva GM, Belorusova AE, Gulyaev MV, Tsitrin EB, Grinenko NF, Gurina OI, Pirogov YA. Targeted delivery of liposomal nanocontainers to the peritumoral zone of glioma by means of monoclonal antibodies against GFAB and the extracellular loop of Cx43. Nanomed. 2012; 8: 63-70.
134. Pirollo KF, Dagata J, Wang P, Freedman M, Vladar A, Fricke S, Ileva L, Zhou Q, Chang EH. A tumor-targeted nanodelivery system to improve early MRI detection of cancer. Mol. Imaging, 2006; 5: 41-52.
135. Erdogan S, Medarova ZO, Roby A, Moore A, Torchilin VA. Enhanced tumor MR imaging with gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes. J. Magn. Reson. Imaging, 2008; 27: 574-580.
136. Van Bochove GS, Sanders HMHF, de Smet M, Keizer HM, Mulder WJM, Krams R, Strijkers GJ, Nicolay K. Molecular MR imaging of collagen in mouse atherosclerosis by using paramagnetic CNA35 micelles. Eur. J. Inorg. Chem. 2012; 2012: 2115-2125.
137. Klink A, Heynens J, Herranz B, Sanders HM, Strijkers GJ, Nicolay K, Merkx M, Mallat Z, Mulder WJ, Fayad ZA. In vivo characterization of a new abdominal aortic aneurysm mouse model with conventional and molecular MRI. Proc. Int. Soc. Magn. Reson. Med. 2010; 18: 1272.
138. van Tilborg GA, Vucic E, Strijkers GJ, Cormode DP, Mani V, Skajaa T, Reutelingsperger CP, Fayad ZA, Mulder WJ, Nicolay K. Annexin A5-functionalized bimodal nanoparticles for MRI and fluorescence imaging of atherosclerotic plaques. Bioconjug. Chem. 2010; 21: 1794-1803.
139. Mulder WJ, Strijkers GJ, Briley-Saboe KC, Frias JC, Aguinaldo JG, Vucic E, Amirbekian V, Tang C, Chin PT, Nicolay K, Fayad ZA. Molecular imaging of macrophages in atherosclerotic plaques using bimodal PEG-micelles. Magn. Reson. Med. 2007; 58: 1164-1170.
140. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J. Am. Chem. Soc. 2004; 126: 16 316-16 317.
141. Frias JC, Ma YQ, Williams KJ, Fayad ZA, Fisher EA. Properties of a versatile nanoparticle platform contrast agent to image and characterize atherosclerotic plaques by magnetic resonance imaging. Nano Lett. 2006; 6: 2220-2224.
142. Cormode DP, Skajaa T, van Schooneveld MM, Koole R, Jarzyna P, Lobatto ME, Calcagno C, Barazza A, Gordon RE, Zanzonico P, Fisher EA, Fayad ZA, Mulder WJ. Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett. 2008; 8: 3715-3723.
143. Cormode DP, Frias JC, Ma Y, Chen W, Skajaa T, Briley-Saebo K, Barazza A, Williams KJ, Mulder WJ, Fayad ZA, Fisher EA. HDL as a contrast agent for medical imaging. Clin. Lipidol. 2009; 4: 493-500.
144. Skajaa T, Cormode DP, Falk E, Mulder WJ, Fisher EA, Fayad ZA. High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2010; 30: 169-176.
145. 3-integrin and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J. Control. Release, 2012; 158: 207-214.
146. 3 integrin and galectin-1 with heteromultivalent paramagnetic liposomes for combined MR imaging and treatment of angiogenesis. Nano Lett. 2010; 10: 52-58.
147. Torchilin VP, Omelyanenko VG, Papisov MI, Bogdanov AA Jr, Trubetskoy VS, Herron JN, Gentry CA. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta, 1994; 1195: 11-20.
148. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 1999; 51: 691-743.
149. van Tilborg GA, Strijkers GJ, Pouget EM, Reutelingsperger CP, Sommerdijk NA, Nicolay K, Mulder WJ. Kinetics of avidin-induced clearance of biotinylated bimodal liposomes for improved MR molecular imaging. Magn. Reson. Med. 2008; 60: 1444-1456.
150. van Tilborg GA, Mulder WJ, van der Schaft DW, Reutelingsperger CP, Griffioen AW, Strijkers GJ, Nicolay K. Improved magnetic resonance molecular imaging of tumor angiogenesis by avidin-induced clearance of nonbound bimodal liposomes. Neoplasia, 2008; 10: 1459-1469.
151. Koning GA, Schiffelers RM, Wauben MH, Kok RJ, Mastrobattista E, Molema G, ten Hagen TL, Storm G. Targeting of angiogenic endothelial cells at sites of inflammation by dexamethasone phosphate-containing RGD peptide liposomes inhibits experimental arthritis. Arthritis Rheum. 2006; 54: 1198-1208.
152. Wirrwar A, Buchholz D, Gottschalk O, Viehöver S, Schramm NU, Müller HW. Dynamic observation of the three-dimensional distribution of labeled liposomes using the novel high-resolution single-photon emission computed tomography. Mol. Imaging 2008; 7: 234-238.
153. Morcos SK. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br. J. Radiol. 2007; 80: 73-76.
154. 1 mapping of the mouse heart using variable flip angle steady-state MR imaging. NMR Biomed. 2011; 24: 154-162.
155. Delli Castelli D, Dastrù W, Terreno E, Cittadino E, Mainini F, Torres E, Spadaro M, Aime S. In vivo MRI multicontrast kinetic analysis of the uptake and intracellular trafficking of paramagnetically labeled liposomes. J. Control. Release, 2010; 144: 271-279.
156. Ward KM, Aletras AH, Balaban RS. A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST). J. Magn. Reson. 2000; 143: 79-87.
157. Zhang SR, Trokowski R, Sherry AD. A paramagnetic CEST agent for imaging glucose by MRI. J. Am. Chem. Soc. 2003; 125: 15 288-15 289.
158. Zhang SR, Malloy CR, Sherry AD. MRI thermometry based on PARACEST agents. J. Am. Chem. Soc. 2005; 127: 17 572-17 573.
159. Zhou JY, van Zijl PCM. Chemical exchange saturation transfer imaging and spectroscopy. Prog. Nucl. Magn. Reson. Spectrosc. 2006; 48: 109-136.
160. Aime S, Delli Castelli D, Terreno E. Highly sensitive MRI chemical exchange saturation transfer agents using liposomes. Angew. Chem. 2005; 44: 5513-5515.
161. Delli Castelli D, Gianolio E, Crich SG, Terreno E, Aime S. Metal containing nanosized systems for MR-molecular imaging applications. Coord. Chem. Rev. 2008; 252: 2424-2443.
162. Delli Castelli D, Terreno E, Carrera C, Giovenzana GB, Mazzon R, Rollet S, Visigalli M, Aime S. Lanthanide-loaded paramagnetic liposomes as switchable magnetically oriented nanovesicles. Inorg. Chem. 2008; 47: 2928-2930.
163. Burdinski D, Pikkemaat JA, Emrullahoglu M, Costantini F, Verboom W, Langereis S, Grüll H, Huskens J. Targeted lipoCEST contrast agents for magnetic resonance imaging: alignment of aspherical liposomes on a capillary surface. Angew. Chem. Int. Ed Engl. 2010; 49: 2227-2229.
164. Kelkar SS, Reineke TM. Theranostics: combining imaging and therapy. Bioconjug. Chem. 2011; 22: 1879-1903.
165. Crommelin DJ, Storm G. Liposomes: from the bench to the bed. J. Liposome Res. 2003; 13: 33-36.
166. Lobatto ME, Fayad ZA, Silvera S, Vucic E, Calcagno C, Mani V, Dickson SD, Nicolay K, Banciu M, Schiffelers RM, Metselaar JM, van Bloois L, Wu HS, Fallon JT, Rudd JH, Fuster V, Fisher EA, Storm G, Mulder WJ. Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. Mol. Pharm. 2010; 7: 2020-2029.
167. Kluza E, Yeo SY, Schmid S, van der Schaft DW, Boekhoven RW, Schiffelers RM, Storm G, Strijkers GJ, Nicolay K. Anti-tumor activity of liposomal glucocorticoids: the relevance of liposome-mediated drug delivery, intratumoral localization and systemic activity. J. Control. Release, 2011; 151: 10-17.
168. Cittadino E, Ferraretto M, Torres E, Maiocchi A, Crielaard BJ, Lammers T, Storm G, Aime S, Terreno E. MRI evaluation of the antitumor activity of paramagnetic liposomes loaded with prednisolone phosphate. Eur. J. Pharm. Sci. 2011; 45: 436-441.
169. Grange C, Crich SG, Esposito G, Alberti D, Tei L, Bussolati B, Aime S, Camussi G. Combined delivery and magnetic resonance imaging of neural cell adhesion molecule-targeted doxorubicin-containing liposomes in experimentally induced Kaposi's sarcoma. Cancer Res. 2010; 70: 2180-2190.
170. Grüll H, Langereis S. Hyperthermia-triggered drug delivery from temperature-sensitive liposomes using MRI-guided high intensity focused ultrasound. J. Control. Release, 2012; 161: 317-327.
171. Torres E, Mainini F, Napolitano R, Fedeli F, Cavalli R, Aime S, Terreno E. Improved paramagnetic liposomes for MRI visualization of pH triggered release. J. Control. Release, 2011; 154: 196-202.
172. Yudina A, de Smet M, Lepetit-Coiffe M, Langereis S, Van Ruijssevelt L, Smirnov P, Bouchaud V, Voisin P, Grüll H, Moonen CT. Ultrasound-mediated intracellular drug delivery using microbubbles and temperature-sensitive liposomes. J. Control. Release, 2011; 155: 442-448.
173. Yudina A, Lepetit-Coiffe M, De Smet M, Langereis S, Grüll H, Moonen C. In vivo temperature controlled ultrasound-mediated intracellular delivery of cell-impermeable compounds. J. Control. Release, 2012; 161: 90-97.
174. Evans E, Needham D. Physical-properties of surfactant bilayer-membranes: thermal transitions, elasticity, rigidity, cohesion, and colloidal interactions. J. Phys. Chem. 1987; 91: 4219-4228.
175. Yatvin MB, Weinstein JN, Dennis WH, Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science, 1978; 202: 1290-1293.
176. Weinstein JN, Magin RL, Yatvin MB, Zaharko DS. Liposomes and local hyperthermia: selective delivery of methotrexate to heated tumors. Science, 1979; 204: 188-191.
177. Needham D, Anyarambhatla G, Kong G, Dewhirst MW. A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res. 2000; 60: 1197-1201.
178. Needham D, Dewhirst MW. The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv. Drug Deliv. Rev. 2001; 53: 285-305.
179. Banno B, Ickenstein LM, Chiu GNC, Bally MB, Thewalt J, Brief E, Wasan EK. The functional roles of poly(ethylene glycol)-lipid and lysolipid in the drug retention and release from lysolipid-containing thermosensitive liposomes in vitro and in vivo. J. Pharm. Sci. 2009; 99: 2295-2308.
180. Ickenstein LM, Arfvidsson MC, Needham D, Mayer LD, Edwards K. Disc formation in cholesterol-free liposomes during phase transition. Biochim. Biophys. Acta, 2003; 1614: 135-138.
181. Kong G, Anyarambhatla G, Petros WP, Braun RD, Colvin OM, Needham D, Dewhirst MW. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 2000; 60: 6950-6957.
182. Lindner LH, Eichhorn ME, Eibl H, Teichert N, Schmitt-Sody M, Issels RD, Dellian M. Novel temperature-sensitive liposomes with prolonged circulation time. Clin. Cancer Res. 2004; 10: 2168-2178.
183. Hossann M, Wiggenhorn M, Schwerdt A, Wachholz K, Teichert N, Eibl H, Issels RD, Lindner LH. In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes. Biochim. Biophys. Acta, 2007; 1768: 2491-2499.
184. Hossann M, Wang T, Wiggenhorn M, Schmidt R, Zengerle A, Winter G, Eibl H, Peller M, Reiser M, Issels RD, Lindner LH. Size of thermosensitive liposomes influences content release. J. Control. Release, 2010; 147: 436-443.
185. Hossann M, Syunyaeva Z, Schmidt R, Zengerle A, Eibl H, Issels RD, Lindner LH. Proteins and cholesterol lipid vesicles are mediators of drug release from thermosensitive liposomes. J. Control. Release, 2012; 162: 400-406.
186. Fossheim SL, Il'yasov KA, Hennig J, Bjornerud A. Thermosensitive paramagnetic liposomes for temperature control during MR imaging-guided hyperthermia: in vitro feasibility studies. Acad. Radiol. 2000; 7: 1107-1115.
187. De Zwart JA, Salomir R, Vimeux F, Klaveness J, Moonen CTW. On the feasibility of local drug delivery using thermo-sensitive liposomes and MR-guided focused ultrasound. Proc. Int. Soc. Magn. Reson. Med. 2000; 43.
188. Viglianti BL, Ponce AM, Michelich CR, Yu D, Abraham SA, Sanders L, Yarmolenko PS, Schroeder T, MacFall JR, Barboriak DP, Colvin OM, Bally MB, Dewhirst MW. Chemodosimetry of in vivo tumor liposomal drug concentration using MRI. Magn. Reson. Med. 2006; 56: 1011-1018.
189. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, Bally MB, Dewhirst MW. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J. Natl. Cancer Inst. 2007; 99: 53-63.
190. de Smet M, Langereis S, Van Den Bosch S, Grüll H. Temperature-sensitive liposomes for doxorubicin delivery under MRI guidance. J. Control. Release, 2010; 143: 120-127.
191. de Smet M, Heijman E, Langereis S, Hijnen NM, Grüll H. Magnetic resonance imaging of high intensity focused ultrasound mediated drug delivery from temperature-sensitive liposomes: an in vivo proof-of-concept study. J. Control. Release, 2011; 150: 102-110.
192. Negussie AH, Yarmolenko PS, Partanen A, Ranjan A, Jacobs G, Woods D, Bryant H, Thomasson D, Dewhirst MW, Wood BJ, Dreher MR. Formulation and characterisation of magnetic resonance imageable thermally sensitive liposomes for use with magnetic resonance-guided high intensity focused ultrasound. Int. J. Hyperthermia, 2011; 27: 140-155.
193. Staruch R, Chopra R, Hynynen K. Localised drug release using MRI-controlled focused ultrasound hyperthermia. Int. J. Hyperthermia, 2011; 27: 156-171.
194. 19F contrast agent for MR image-guided drug delivery. J. Am. Chem. Soc. 2009; 131: 1380-1381.
195. Viglianti BL, Abraham SA, Michelich CR, Yarmolenko PS, MacFall JR, Bally MB, Dewhirst MW. In vivo monitoring of tissue pharmacokinetics of liposome/drug using MRI: illustration of targeted delivery. Magn. Reson. Med. 2004; 51: 1153-1162.
196. Spuentrup E, Botnar RM, Wiethoff AJ, Ibrahim T, Kelle S, Katoh M, Ozgun M, Nagel E, Vymazal J, Graham PB, Gunther RW, Maintz D. MR imaging of thrombi using EP-2104R, a fibrin-specific contrast agent: initial results in patients. Eur. Radiol. 2008; 18: 1995-2005.
197. Matsumura Y, Gotoh M, Muro K, Yamada Y, Shirao K, Shimada Y, Okuwa M, Matsumoto S, Miyata Y, Ohkura H, Chin K, Baba S, Yamao T, Kannami A, Takamatsu Y, Ito K, Takahashi K. Phase I and pharmacokinetic study of MCC-465, a doxorubicin (DXR) encapsulated in PEG immunoliposomes, in patients with metastatic stomach cancer. Ann. Oncol. 2004; 15: 517-525.
198. Senzer NN, Matsuno K, Yamagata N, Fujisawa T, Wasserman E, Sutherland W, Sharma S, Phan A. MPB-426, a novel liposome encapsulated oxaliplatin, in combination with 5-FU/leucovorin (LV): phase I results of a phase I/II study in gastro-esophagal adenocarcinoma, with pharmacokinetics. Mol. Cancer Ther. 2009; 8: C36.
199. Ciesienski KL, Yang Y, Ay I, Chonde DB, Loving GS, Rietz TA, Catana C, Caravan P. Fibrin-targeted PET probes for the detection of thrombi. Mol. Pharmaceutics, 2013; 10: 1100-1110.
200. Pichler BJ, Kolb A, Nägele T, Schlemmer H-P. PET/MRI: paving the way for the next generation of clinical multimodality imaging applications. J. Nucl. Med. 2010; 51: 333-336.
201. Li S, Goins B, Zhang L, Bao A. Novel multifunctional theranostic liposome drug delivery system: construction, characterization, and multimodality MR, near-infrared fluorescent, and nuclear imaging. Bioconjug. Chem. 2012; 23: 1322-1332.